-
Electronic (PDF)
-
Site License
-
Enterprisewide
Mild Cognitive Impairment - Pipeline Review, H1 2012
Global Markets Direct, April 2012, Pages: 120
Mild Cognitive Impairment – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H1 2012', provides an overview of the Mild Cognitive Impairment therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. 'Mild Cognitive Impairment - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Mild Cognitive Impairment.
- A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mild Cognitive Impairment pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Mild Cognitive Impairment therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Mild Cognitive Impairment Therapeutic Products under Development, Key Players in Mild Cognitive Impairment Therapeutics, Mild Cognitive Impairment Pipeline Overview, Mild Cognitive Impairment Pipeline, Mild Cognitive Impairment Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mild Cognitive Impairment Overview
Therapeutics Development
An Overview of Pipeline Products for Mild Cognitive Impairment
Mild Cognitive Impairment Therapeutics under Development by Companies
Mild Cognitive Impairment Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Mild Cognitive Impairment Therapeutics – Products under Development by Companies
Mild Cognitive Impairment Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Mild Cognitive Impairment Therapeutics Development
Boehringer Ingelheim GmbH
Albany Molecular Research, Inc.
Sutter Health
Chiesi Farmaceutici SpA
Theratechnologies Inc.
Allon Therapeutics Inc.
Suven Life Sciences Ltd.
Mithridion, Inc.
QR Pharma, Inc.
Adeona Pharmaceuticals, Inc.
Krenitsky Pharmaceuticals Inc.
Galenea Corp.
Pherin Pharmaceuticals, Inc.
Mild Cognitive Impairment – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-108 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Posiphen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCD-386CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tesamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
reaZin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-HT6 Modulators - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHF 5074 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP544 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BF2.649 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naltrexone + Marijuana - Drug Profile
Product Description
Mechanism of Action
R&D Progress
17B-Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolcapone + Entacapone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Navoban + Risperdal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atomoxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregnenolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D Serine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cannabidiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candesartan + Nifedipine + Metoprolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lisinopril + Nifedipine + Metoprolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Sodium Thiosulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Disulfiram + CM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH9507 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transdermal nicotine patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ginkgo Biloba - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Remifentanil + Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-HT6 Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NewGam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ladostigil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-507 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-976 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Histamine-3 Antagonist For Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Neuro Degenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-HT4 Agonist And Partial Agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCA909 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin Detemir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDE 2 Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mild Cognitive Impairment Therapeutics – Drug Profile Updates
Mild Cognitive Impairment Therapeutics – Discontinued Products
Mild Cognitive Impairment Therapeutics - Dormant Products
Mild Cognitive Impairment – Product Development Milestones
Featured News & Press Releases
Oct 20, 2011: Prana Biotechnology Announces Australian Federal Government Grant To Study Effect Of PBT2 In Ageing Brain
Oct 13, 2011: QR Pharma Reports Results From SBIR Grant By NIA/NIH To Study Posiphen And Metabolites In Various Models
Apr 20, 2011: Neurokine Selects Clinical Trial Sites For NK-001 Phase II Study
Apr 14, 2011: Adeona's Clinical Study Of reaZin Meets Primary Outcomes Of Increasing Serum Zinc And Decreasing Serum Free Copper
Feb 10, 2011: Allon Granted Key Japanese Patent For Davunetide
Feb 03, 2011: Neurokine Signs Contract With Clinical Investigation Group To Initiate Phase II NK-001 Human Clinical Trials In Europe
Nov 30, 2010: Aphios Awarded Phase I of Fast Track SBIR Grant from National Institute of Aging for Novel Alzheimer's Disease Nanodrug
Oct 06, 2010: Adeona Completes 100% Enrollment In Pivotal Alzheimer’s Disease And Mild Cognitive Impairment Clinical Study
Jun 07, 2010: Adeona Completes 50% Enrollment In Part Two Of CopperProof-2 Study In Alzheimer's Disease Patients
May 11, 2010: Allon Announces Publication Of Davunetide Data Demonstrating Cognition Improvement In Schizophrenia Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Mild Cognitive Impairment, H1 2012
Products under Development for Mild Cognitive Impairment – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Boehringer Ingelheim GmbH, H1 2012
Albany Molecular Research, Inc., H1 2012
Sutter Health, H1 2012
Chiesi Farmaceutici SpA, H1 2012
Theratechnologies Inc., H1 2012
Allon Therapeutics Inc., H1 2012
Suven Life Sciences Ltd., H1 2012
Mithridion, Inc., H1 2012
QR Pharma, Inc., H1 2012
Adeona Pharmaceuticals, Inc., H1 2012
Krenitsky Pharmaceuticals Inc., H1 2012
Galenea Corp., H1 2012
Pherin Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Mild Cognitive Impairment Therapeutics – Drug Profile Updates
Mild Cognitive Impairment Therapeutics – Discontinued Products
Mild Cognitive Impairment Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Mild Cognitive Impairment, H1 2012
Products under Development for Mild Cognitive Impairment – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
